← Back to headlines
Raymond James Resumes Outperform Coverage on Jazz Pharmaceuticals (JAZZ)
Raymond James has reinstated its coverage of Jazz Pharmaceuticals (JAZZ), assigning an Outperform rating to the company's stock.
20 Apr, 00:07 — 20 Apr, 00:07
Sources
Showing 1 of 1 sources
